Clinical Learning Study for a Mobile Smoking Cessation Program

Smoking Cessation Clinical Trial

Official title:

An Exploratory, Observational, Open-label, Remote Study of Clickotine: A Digital Therapeutic

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04857515
• Other study ID #: CT-101-CLS-001
• Status: Completed
• Start date: March 12, 2021
• Est. completion date: June 28, 2021

Study information

• Verified date: August 2021
• Source: Click Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study are to obtain learnings regarding the Digital Therapeutic (DTx) experience of Clickotine, including acceptability and preference of the overall program and specific DTx components, as well as to obtain learnings related to adult participants' use of the DTx for smoking cessation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 78
• Est. completion date: June 28, 2021
• Est. primary completion date: June 28, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed informed consent.
• Age 18 and older.
• For cigarette smokers: Smokes at least 5 cigarettes a day. For dual-users: Smokes

cigarettes AND uses e-cigarettes, with the following additional criteria:

• Smokes at least 5 cigarettes a day
• Vaping sessions, when they occur, must be for at least 10 minutes (15 puffs)
• Fluent in written and spoken English (confirmed by ability to read and comprehend the informed consent form)
• Lives in the United States.
• Is the solo user of an iPhone with iPhone operating system (iOS)13 or greater capabilities or a smart phone with an Android operating system (OS) 9 or greater capabilities.
• Has an active email address.
• Willing and able to receive SMS text messages on their smartphone and email messages.
• Have access to internet connection during the study duration.
• Able to confirm download of installed DTx on baseline date.
• Willing and able to comply with study protocol and assessments.
• Is willing and able to self-identify sessions of cigarette smoking (1 or more consecutive cigarettes) or vaping (approximately 15 puffs or around 10 minutes in duration) and log those sessions.
• Self-reported comfort with and ability to use smartphone apps/programs.

Exclusion Criteria:

• Prior use of Clickotine.
• Currently using a software app for smoking cessation.
• Lifetime diagnosis of schizophrenia, psychotic disorder, or pervasive developmental disorders, as per participant self-report.
• Any unstable medical illnesses including hepatic, renal, gastroenterological, respiratory, cardiovascular, endocrine, neurologic (including history of severe head injury with loss of consciousness), immunologic, or hematologic disease, as per participant self-report.
• Other significant medical condition that, in the opinion of the Investigator or study sponsor, may cofound the interpretation of device efficacy, safety, and tolerability.
• Current use of tobacco-containing products other than cigarettes or e-cigarettes (e.g. snuff, chewing tobacco, cigars, or pipes).
• Does not have or is unwilling to create a PayPal account

Related Conditions & MeSH terms

• Nicotine Dependence
• Smoking
• Smoking Behaviors
• Smoking Cessation
• Smoking Reduction
• Smoking, Cigarette
• Tobacco Use Disorder

Intervention

Device:
• Clickotine®
Clickotine is a DTx that contains behavior modification techniques that include controlled breathing, social engagement, personalized messaging, medication access and adherence, digital diversions, and financial incentives.

Locations

Country	Name	City	State
United States	Click Therapeutics	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Click Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The main outcome of the Clickotine Learning Study is to determine acceptability of the digital intervention (DTx).	General acceptability of the DTx will be evaluated via surveys for all participants	4 Months
Primary	The main outcome of the Clickotine Learning Study is to determine engagement with the digital intervention (DTx).	Engagement with the digital intervention will be measured via app use for all participants	4 Months
Primary	The main outcome of the Clickotine Learning Study is to evaluate attitudes and beliefs regarding the digital intervention.	Attitudes and beliefs regarding the digital intervention will be evaluated by interview for selected participants	4 Months
Secondary	The secondary outcome of the Clickotine Learning Study is to measure engagement levels with the digital intervention for cigarette smokers as compared to dual-users	These engagement levels will be measured via app use.	4 Months
Secondary	The secondary outcome of the Clickotine Learning Study is to determine acceptability of the digital intervention for cigarette users as compared to dual-users	Acceptability of the digital intervention will be evaluated via survey	4 Months